FindTrial
Sign In

PET/MR in Locally Advanced Nasopharyngeal Carcinoma

PET/MR in Locally Advanced Nasopharyngeal Carcinoma

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03657017
Enrollment
150
Registered
2018-09-04
Start date
2018-06-01
Completion date
2025-12-30
Last updated
2018-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Carcinoma, PET/MR

Brief summary

PET/MR in Locally Advanced Nasopharyngeal Carcinoma

Interventions

DIAGNOSTIC_TESTPET/MR

Performed on a hybrid PET/MR scanner before treatment start (N = 150). Among those patients, 10 patients are examined with PET/MR in the completion of neoadjuvant chemotherapy and a follow-up scan three months after the completion of radiotherapy.

Sponsors

Zhejiang Cancer Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients with newly histologically confirmed non-keratinizing carcinoma. * Tumor staged T1-4N0-3M0 （according to the 8th AJCC staging system） * Performance status: KPS\>70 * With normal liver function test (ALT, AST \<1.5ULN) * Renal: creatinine clearance \>60ml/min * Without hematopathy,marrow: WBC \>4\*109/L, HGB\>80G/L, and PLT\>100\*109/L. * Written informed consent

Exclusion criteria

* Adenocarcinoma * Age \>70 * Prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin) * Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume) * Patient is pregnant or lactating * Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×ULN), or emotional disturbance.

Design outcomes

Primary

MeasureTime frameDescription
Multiparametric PET/MRI-based radiomics nomograms for locally advanced nasopharyngeal carcinomaFrom day 1 of chemotherapy to the date of the event, a minimum follow-up of 3 years.Radiomics-based prognostic model by PET/MRI

Secondary

MeasureTime frameDescription
Prediction model of the efficiency of treatment in locally advanced nasopharyngeal carcinomaabout 4 years (all of patients complete treatment)Radiomics-based prediction model of the efficiency of treatment by PET/MRI

Countries

China

Contacts

Primary ContactCaineng Cao, MD
caocaineng777@sina.com0571-88128202

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026